Thursday, Masimo Corp. (MASI) said it has signed a multi-year technology licensing agreement with CareFusion Corp. (CFN) for establishing the breakthrough noninvasive blood constituent monitoring capabilities of Masimo Rainbow SET Pulse CO-Oximetry technology to be used in CareFusion infusion and respiratory products under development.
Masimo said that incorporating Masimo Rainbow SET Pulse CO-Oximetry technology will enable CareFusion's future infusion and respiratory products to noninvasively and continuously measure multiple blood constituents to more accurately assess dyshemoglobins affecting oxygenation, predict fluid responsiveness, and provide earlier identification of respiratory compromise.
Currently, CareFusion uses Masimo technology in the Alaris SpO2 module to help safeguard PCA delivery through the Alaris System. The Alaris PCA module together with the Alaris SpO2 module--featuring Masimo SET pulse oximetry technology for accurate and trustworthy measure-through motion and low-perfusion SpO2, pulse rate, and perfusion index measurements--provides an additional safety net for risk factors not covered by programming safety and bar coding, such as previously undiagnosed clinical conditions and PCA by proxy.
For comments and feedback contact: editorial@rttnews.com
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.